Innovative Strategies For Developing And Enhancing Perfusion Platforms In Bioreactor Scale-Up

Transitioning from traditional fed-batch to modern perfusion cell culture platforms is a key strategy for biopharmaceutical manufacturers seeking to lower costs and increase product yield for recombinant proteins, such as monoclonal antibodies. Perfusion systems offer advantages like a smaller manufacturing footprint, longer production periods—over 30 days compared to 14 for standard fed-batch—and the capacity to quickly change production from one product to another.

Effectively moving to a perfusion process requires carefully selecting an optimal cell culture medium for a specific cell line. This selection process can be streamlined by using cost-effective, small-scale models like spin/shake tubes and microbioreactors to mimic perfusion conditions and evaluate key metrics like cell specific productivity (qP), volumetric productivity (VP), and cell specific perfusion rate (CSPR). These small-scale mimics act as essential performance indicators, helping to identify media candidates capable of successfully scaling up to a true perfusion bioreactor. Dive into the full application note to learn the specifics of this media evaluation strategy.